Limited Review Report issued by the Statutory Auditors of the Company for the quarter
As filed · Alembic Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on November 04, 2026.
RoutineLowmateriality 26 out of 100
What happened
Factthe Limited Review Report issued by the Statutory Auditors of the Company for the quarter. The time of commencement of Board Meeting was 11 :30 a.m. and the time of conclusion.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Debt
WithdrawnEarlierQ1 FY27
gross debt was about -- we are at around INR1,600 crores of gross debt.
NowQ1 FY27
we should see this debt levels moderating.
Change
FactGuidance withdrawn
Implication
CapitSignal interpretationDetected a change between two statements on this topic.confidence 60%
Watch next
Fact- I think about 15-odd percent or so of what I've guided for that the business will grow, and I think we're quit (management committed by FY27)
- Expenditures on artificial intelligence within the healthcare sector are anticipated to attain a value of US$ (management committed by FY30)
Evidence
- Alembic Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- BOARD_MEETING base 22; +4 corroborating keywords; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%